Atopic dermatitis (AD) is a skin condition characterized by a rash and itching, resulting from skin inflammation. Ivarmacitinib is an approved medication for treating AD.
This study aims to evaluate the effectiveness and safety of Ivarmacitinib in the treatment of moderate-to-severe atopic dermatitis under real-world conditions. It will assess the time to pruritus improvement and skin lesion clearance, collect large-sample safety data, analyze disease improvement across patient subgroups with different baseline characteristics, and explore the impact of various maintenance treatment regimens on disease recurrence.
It is expected that there will be no additional burden for participants in this trial.
Aged between 12 and 75 years;
Diagnosed with moderate-to-severe atopic dermatitis (AD) ;
Participants (and legal representatives for adolescents) able to understand and communicate with the investigator.
Absolute lymphocyte count of <0.50 x 10^9 /L (<500/mm3);
Absolute Neutrophil Count (ANC) of <1 X 10^9/L (<1000/mm3);
Hemoglobin level < 80 g/L.
Subject has any malignancies or has a history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ.